Author Correction: Plasma bioactive adrenomedullin predicts mortality and need for dialysis in critical COVID-19
Patrik Johnsson, Theodor Sievert, Ingrid Didriksson, Hans Friberg, Attila Frigyesi
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNeuropeptides and Animal Physiology · Thermal Regulation in Medicine · Cancer, Stress, Anesthesia, and Immune Response
Correction to: Scientific Reports 10.1038/s41598-024-74380-x, published online 11 October 2024
The original version of this Article contained an error in Figure 3 and 4 where the graphs were incorrectly labelled. The original Figure 3 and 4 and the accompanying legends appear below.Fig. 3. Bio-ADM tertiles and survival in severe COVID-19, from ICU admission, day 2, and day 7. Bio-ADM: circulating bioactive adrenomedullin; ICU: intensive care unit.Fig. 4. Bio-ADM tertiles and RRT-free survival, from ICU admission, day 2, and day 7. Bio-ADM: circulating bioactive adrenomedullin; RRT: renal replacement therapy; ICU: intensive care unit.
The original Article has been corrected.